Neurosoft Bioelectronics SA

Neurosoft Bioelectronics, headquartered in Geneva, Switzerland, focuses on the development of advanced brain-computer interfaces that enhance bio-integration with neural tissues through innovative, elastic designs. Founded in 2020, Neurosoft Bioelectronics SA specializes in brain-computer interface technology. The company has completed one funding deal, raising USD 7. 5 mn in Seed funding in May 2026, led by Skybound Venture Capital, with participation from Connecticut Innovations, IAG Capital Partners, and Protocol Labs, Inc.

The total amount raised to date is USD 7. 5 mn. Neurosoft Bioelectronics specializes in developing advanced brain-computer interfaces (BCIs) characterized by their soft and elastic design, which allows superior bio-integration with neural tissues. Their products are significantly softer and thinner than conventional solutions, improving the safety profile of long-term BCIs and minimizing scar tissue formation associated with neural implants.

These technologies facilitate minimally invasive brain implantation, broadening clinical applications particularly for neurological disorders, targeting healthcare providers and research institutions primarily in the United States and Europe. The company generates revenue through direct sales and partnerships with healthcare providers and research institutions, focusing on investigational brain-computer interfaces integrated into therapeutic solutions for neurological conditions. Transactions typically involve collaborations where Neurosoft Bioelectronics supplies its products for patient care, with pricing structures based on contractual agreements reflecting the technological advancements of their offerings. In May 2026, Neurosoft Bioelectronics SA raised USD 7.

5 mn in Seed funding to advance clinical milestones and support the commercialization of its brain-computer interface technology. The company aims to design and launch new products targeting specific neurological applications, with plans for expansion into additional markets across Europe and North America by mid-2027. The recent funding will enable the company to enhance its product development and market reach.